Search Results - "Fecci, Peter E"

Immune suppression in gliomas by Grabowski, Matthew M., Sankey, Eric W., Ryan, Katherine J., Chongsathidkiet, Pakawat, Lorrey, Selena J., Wilkinson, Daniel S., Fecci, Peter E.

“…Introduction The overall survival in patients with gliomas has not significantly increased in the modern era, despite advances such as immunotherapy. This is…”
Get full text

Current multidisciplinary management of brain metastases by Moravan, Michael J., Fecci, Peter E., Anders, Carey K., Clarke, Jeffrey M., Salama, April K. S., Adamson, Justus D., Floyd, Scott R., Torok, Jordan A., Salama, Joseph K., Sampson, John H., Sperduto, Paul W., Kirkpatrick, John P.

“…Brain metastasis (BM), the most common adult brain tumor, develops in 20% to 40% of patients with late‐stage cancer and traditionally are associated with a…”
Get full text

Leptomeningeal disease: current diagnostic and therapeutic strategies by Nayar, Gautam, Ejikeme, Tiffany, Chongsathidkiet, Pakawat, Elsamadicy, Aladine A, Blackwell, Kimberly L, Clarke, Jeffrey M, Lad, Shivanand P, Fecci, Peter E

“…Leptomeningeal disease has become increasingly prevalent as novel therapeutic interventions extend the survival of cancer patients. Although a majority of…”
Get full text

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy by Giles, Amber J, Hutchinson, Marsha-Kay N D, Sonnemann, Heather M, Jung, Jinkyu, Fecci, Peter E, Ratnam, Nivedita M, Zhang, Wei, Song, Hua, Bailey, Rolanda, Davis, Dionne, Reid, Caitlin M, Park, Deric M, Gilbert, Mark R

“…Corticosteroids are routinely utilized to alleviate edema in patients with intracranial lesions and are first-line agents to combat immune-related adverse…”
Get full text

Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model by Cheema, Tooba A., Wakimoto, Hiroaki, Fecci, Peter E., Ning, Jianfang, Kuroda, Toshihiko, Jeyaretna, Deva S., Martuza, Robert L., Rabkin, Samuel D.

“…Glioblastoma (World Health Organization grade IV) is an aggressive adult brain tumor that is inevitably fatal despite surgery, radiation, and chemotherapy…”
Get full text

Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease by Kemeny, Hanna R, Elsamadicy, Aladine A, Farber, S Harrison, Champion, Cosette D, Lorrey, Selena J, Chongsathidkiet, Pakawat, Woroniecka, Karolina I, Cui, Xiuyu, Shen, Steven H, Rhodin, Kristen E, Tsvankin, Vadim, Everitt, Jeffrey, Sanchez-Perez, Luis, Healy, Patrick, McLendon, Roger E, Codd, Patrick J, Dunn, Ian F, Fecci, Peter E

“…Although pituitary adenoma is classified as benign, Cushing disease is associated with significant morbidity due to the numerous sequelae of elevated cortisol…”
Get full text

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors by Mei, Yu, Bi, Wenya Linda, Greenwald, Noah F, Du, Ziming, Agar, Nathalie Y R, Kaiser, Ursula B, Woodmansee, Whitney W, Reardon, David A, Freeman, Gordon J, Fecci, Peter E, Laws, Jr, Edward R, Santagata, Sandro, Dunn, Gavin P, Dunn, Ian F

“…Subsets of pituitary tumors exhibit an aggressive clinical courses and recur despite surgery, radiation, and chemotherapy. Because modulation of the immune…”
Get full text

Neuronal CaMKK2 promotes immunosuppression and checkpoint blockade resistance in glioblastoma by Tomaszewski, William H., Waibl-Polania, Jessica, Chakraborty, Molly, Perera, Jonathan, Ratiu, Jeremy, Miggelbrink, Alexandra, McDonnell, Donald P., Khasraw, Mustafa, Ashley, David M., Fecci, Peter E., Racioppi, Luigi, Sanchez-Perez, Luis, Gunn, Michael D., Sampson, John H.

“…Glioblastoma (GBM) is notorious for its immunosuppressive tumor microenvironment (TME) and is refractory to immune checkpoint blockade (ICB). Here, we identify…”
Get full text

The intersection between immunotherapy and laser interstitial thermal therapy: a multipronged future of neuro-oncology by Srinivasan, Ethan S., Sankey, Eric W., Grabowski, Matthew M., Chongsathidkiet, Pakawat, Fecci, Peter E.

“…The rise of immunotherapy (IT) in oncological treatment has greatly improved outcomes in a number of disease states. However, its use in tumors of the central…”
Get full text

Risk of Tract Seeding Following Laser Interstitial Thermal Therapy for Brain Tumors by Haskell-Mendoza, Aden P, Srinivasan, Ethan S, Lerner, Emily C, Edwards, Ryan M, Schwalb, Allison M, Jackson, Joshua D, Hardigan, Andrew A, Vaios, Eugene J, Fecci, Peter E

“…The management of intracranial oncological disease remains a significant challenge despite advances in systemic cancer therapy. Laser interstitial thermal…”
Get full text

Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory by Liu, Yang, Chongsathidkiet, Pakawat, Crawford, Bridget M, Odion, Ren, Dechant, Cosette A, Kemeny, Hanna R, Cui, Xiuyu, Maccarini, Paolo F, Lascola, Christopher D, Fecci, Peter E, Vo-Dinh, Tuan

“…Brain tumors present unique therapeutic challenges and they include glioblastoma (GBM) and metastases from cancers of other organs. Current treatment options…”
Get full text

Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies by Waibl Polania, Jessica, Lerner, Emily C, Wilkinson, Daniel S, Hoyt-Miggelbrink, Alexandra, Fecci, Peter E

“…Successful cancer immunotherapies rely on a replete and functional immune compartment. Within the immune compartment, T cells are often the effector arm of…”
Get full text

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma by Suryadevara, Carter M., Desai, Rupen, Abel, Melissa L., Riccione, Katherine A., Batich, Kristen A., Shen, Steven H., Chongsathidkiet, Pakawat, Gedeon, Patrick C., Elsamadicy, Aladine A., Snyder, David J., Herndon, James E., Healy, Patrick, Archer, Gary E., Choi, Bryan D., Fecci, Peter E., Sampson, John H., Sanchez-Perez, Luis

“…Adoptive transfer of T cells expressing chimeric antigen receptors (CARs) is an effective immunotherapy for B-cell malignancies but has failed in some solid…”
Get full text

Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function by Fecci, Peter E, Ochiai, Hidenobu, Mitchell, Duane A, Grossi, Peter M, Sweeney, Alison E, Archer, Gary E, Cummings, Thomas, Allison, James P, Bigner, Darell D, Sampson, John H

“…Purpose: Patients with malignant glioma suffer global compromise of their cellular immunity, characterized by dramatic reductions in CD4 + T cell numbers and…”
Get full text

Navigating the ventricles: Novel insights into the pathogenesis of hydrocephalus by Bramall, Alexa N., Anton, E.S., Kahle, Kristopher T., Fecci, Peter E.

“…Congenital hydrocephalus occurs in one in 500–1000 babies born in the United States and acquired hydrocephalus may occur as the consequence of stroke,…”
Get full text

Prospect of rindopepimut in the treatment of glioblastoma by Elsamadicy, Aladine A, Chongsathidkiet, Pakawat, Desai, Rupen, Woroniecka, Karolina, Farber, S Harrison, Fecci, Peter E, Sampson, John H

“…Rindopepimut (CDX-110) is a peptide vaccine that targets epidermal growth factor receptor variant III (EGFRvIII), a tumor-specific epitope expressed in the…”
Get more information

Editorial: It takes a village: The expanding multi-disciplinary approach to brain metastasis by Fecci, Peter E., Rao, Ganesh, Brastianos, Priscilla K., Dunn, Gavin P., Anders, Carey K.

Get full text

Targeting Immunometabolism in Glioblastoma by Mohan, Aditya A, Tomaszewski, William H, Haskell-Mendoza, Aden P, Hotchkiss, Kelly M, Singh, Kirit, Reedy, Jessica L, Fecci, Peter E, Sampson, John H, Khasraw, Mustafa

“…We have only recently begun to understand how cancer metabolism affects antitumor responses and immunotherapy outcomes. Certain immunometabolic targets have…”
Get full text

CD8 + T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis by Lerner, Emily C, Woroniecka, Karolina I, D'Anniballe, Vincent M, Wilkinson, Daniel S, Mohan, Aditya A, Lorrey, Selena J, Waibl-Polania, Jessica, Wachsmuth, Lucas P, Miggelbrink, Alexandra M, Jackson, Joshua D, Cui, Xiuyu, Raj, Jude A, Tomaszewski, William H, Cook, Sarah L, Sampson, John H, Patel, Anoop P, Khasraw, Mustafa, Gunn, Michael D, Fecci, Peter E

“…The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell killing by CD8 T cells recognizing cognate antigens presented in the…”
Get full text

Immunotherapy of malignant brain tumors by Mitchell, Duane A., Fecci, Peter E., Sampson, John H.

“…Despite aggressive multi‐modality therapy including surgery, radiation, and chemotherapy, the prognosis for patients with malignant primary brain tumors…”
Get full text